SCHEMBL19299698

SCHEMBL19299698

COc1ccccc1C(=O)NNC(=O)COc1ccc(C(C)C)cc1

nearest known ligand 0.72

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.64
HPGD P15428 1/20 0.57
XBP1 P17861 1/20 0.57
ALDH1A1 P00352 2/20 0.55
RECQL P46063 1/20 0.55
KMT2A Q03164 1/20 0.54
STAT3 P40763 1/20 0.53
NPC1 O15118 4/20 0.53
RAB9A P51151 4/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.51
TP53 P04637 1/20 0.51
MAPT P10636 1/20 0.51
MAPK1 P28482 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19299654 0.89 ALDH1A1 (0.60) LMNAHPGDALDH1A1KMT2AMAPT
SCHEMBL5696430 0.75 HCAR2 (0.74) LMNAHPGDALDH1A1KMT2ANPC1
SCHEMBL21416862 0.74 LMNA (0.51) LMNAHPGDXBP1ALDH1A1KMT2A
SCHEMBL19299701 0.74 KMT2A (0.68) ALDH1A1RECQLKMT2ANPC1RAB9A
SCHEMBL19299700 0.74 ALDH1A1 (0.57) LMNAHPGDALDH1A1RECQLKMT2A
SCHEMBL29046243 0.73 HPGD (1.00) LMNAHPGDXBP1ALDH1A1KMT2A
SCHEMBL8430118 0.72 RAB9A (0.68) LMNAHPGDALDH1A1RECQLKMT2A
SCHEMBL19299385 0.72 GAA (0.54) LMNAHPGDALDH1A1RECQLKMT2A
SCHEMBL19294526 0.72 RECQL (0.56) RECQLKMT2ANPC1RAB9AL3MBTL1
SCHEMBL19299704 0.72 RECQL (0.59) ALDH1A1RECQLKMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3212183-B1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS UNIV ROCHESTER (US) 2019-10-02 EP disclosed
US-10028931-B2 Synergistic compositions for treating microbial infections UNIVERSITY OF ROCHESTER (US) 2018-07-24 US disclosed
US-20170246139-A1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS UNIVERSITY OF ROCHESTER (US) 2017-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10028931-B2 Synergistic compositions for treating microbial infections RNASE1, RNASEL, RNASEH1 LMNA 2478/4885HPGD 4332/4885XBP1 1129/4885
US-20170246139-A1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS RNASE1, RNASEL, RNASEH1 LMNA 2478/4885HPGD 4332/4885XBP1 1129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.